Pfizer, Amgen and Janssen seek further clarity on FDA’s new benefit-risk guidance

Three top biopharma companies are seeking more details from the FDA on how the agency conducts its benefit-risk assessments for new drugs and biologics. While Pfizer, Amgen and Janssen praised the agency for further spelling out its thinking on the subject in a new draft guidance, including a discussion of…

...

Click to view original post